Analysis of pathways involved in a positive response to DMF therapy (defined as fulfillment of NEDA-3 criteria) in memory CD8+ T cells from MS patients revealed a significant enrichment for genes associated with the PI3K-AKT-mTOR-pathway (Fig. 3a and Supplementary Fig. 3a) (GSEA, MSigDB, hallmark dataset). The gene discussed is CD8A; the disease is myeloid sarcoma.